FDA Awards Priority Review Voucher to Sponsor of Rare Pediatric Disease Product

Summary

The FDA has awarded a priority review voucher to the sponsor of LAMZEDE, a rare pediatric disease product approved on February 16, 2023, in recognition of meeting specific criteria under the FD&C Act and FDASIA.